Stephen Hoge - Feb 14, 2024 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
President
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Feb 14, 2024
Transactions value $
-$936,981
Form type
4
Date filed
2/16/2024, 04:19 PM
Previous filing
Feb 13, 2024
Next filing
Feb 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Award $0 +22.7K +1.5% $0.00 1.54M Feb 14, 2024 Direct F2
transaction MRNA Common Stock Sale -$937K -10.5K -0.69% $88.88 1.53M Feb 16, 2024 Direct F3
holding MRNA Common Stock 4.12K Feb 14, 2024 By Valhalla, LLC
holding MRNA Common Stock 152K Feb 14, 2024 By Trust F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F2 The reported transaction is the vesting of performance-based restricted stock units granted to the reporting person on March 5, 2021 (the "2021 PSUs").
F3 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the 2021 PSUs. This "sell-to-cover" transaction was mandated by the Issuer's equity incentive plan and does not represent a discretionary trade by the reporting person.